Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02511821
Other study ID # 15051
Secondary ID NCI-2015-0106115
Status Completed
Phase N/A
First received
Last updated
Start date July 22, 2015
Est. completion date July 31, 2016

Study information

Verified date January 2021
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies an electronic monitoring device of patient-reported outcomes (PROs) and function in improving patient-centered care in patients with gastrointestinal cancer undergoing surgery. Electronic monitoring is a technology-based way of asking patients about the quality of life, symptoms, and activity using online surveys and an activity tracking watch may make it easier for patients to tell their doctors and nurses about any issues before and after surgery. Electronic systems of assessing PROs may increase the depth and accuracy of available clinical data, save administrative time, prompt early intervention that improves the patient experience, foster patient-provider communication, improve patient safety, and enhance the consistency of data collection across multiple sites.


Description:

PRIMARY OBJECTIVES: I. To determine the feasibility of administration of electronic patient-reported outcomes and functional assessment in gastrointestinal (GI) cancer surgery (gastric, colorectal, liver, pancreas). II. Determine percentage of patients able to complete > 80% of MD. Anderson Symptom Inventory (MDASI) and European Quality of LIfe-5 Dimensions (EQ-5D) web-based surveys. III. Determine percentage of patients able to wear the wristband device at least 1 week post-operatively. IV. Determine length of time to complete the web-based surveys. V. Determine length of time patients are able to wear the wristband device, before and after surgery. SECONDARY OBJECTIVES: I. Determine the percentage of patients who did not enroll in the study and analyze the reasons why. This will be accomplished using: 1) the number of patients asked to participate; 2) the number of patients who declined to participate, and 3) reasons for declining participation. II. Responses from the Satisfaction Tool will be used to assess: 1) ease of use of web-based surveys and wristband device; 2) feedback on items in the web-based surveys that are distressing or difficult to comprehend; 3) feedback on length of surveys and timing of administration; and 4) suggestions for items that were not covered but should be added. III. Calculate the mean number of missing items within each questionnaire to identify individual or subsets of questions that are difficult to answer. OUTLINE: Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery. After completion of study, patients are followed up for 1 month.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date July 31, 2016
Est. primary completion date July 31, 2016
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Scheduled to undergo surgery for primary or secondary gastric, colorectal, liver, or pancreas cancer - Able to read and understand English - Patients across all stages of disease - There are no restrictions related to performance status or life expectancy - This protocol is eligible for waiver of informed consent documentation; all subjects must have the ability to understand and the willingness to provide verbal informed consent Exclusion Criteria: - Research participants who have no computer and internet access and/or do not use a computer even if one is present in the household - Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Study Design


Related Conditions & MeSH terms

  • Carcinoma, Hepatocellular
  • Colorectal Neoplasms
  • Liver Neoplasms
  • Pancreatic Neoplasms
  • Stage I Adult Liver Cancer
  • Stage I Colorectal Cancer
  • Stage IA Gastric Cancer
  • Stage IA Pancreatic Cancer
  • Stage IB Gastric Cancer
  • Stage IB Pancreatic Cancer
  • Stage II Adult Liver Cancer
  • Stage IIA Colorectal Cancer
  • Stage IIA Gastric Cancer
  • Stage IIA Pancreatic Cancer
  • Stage IIB Colorectal Cancer
  • Stage IIB Gastric Cancer
  • Stage IIB Pancreatic Cancer
  • Stage IIC Colorectal Cancer
  • Stage III Pancreatic Cancer
  • Stage IIIA Adult Liver Cancer
  • Stage IIIA Colorectal Cancer
  • Stage IIIA Gastric Cancer
  • Stage IIIB Adult Liver Cancer
  • Stage IIIB Colorectal Cancer
  • Stage IIIB Gastric Cancer
  • Stage IIIC Adult Liver Cancer
  • Stage IIIC Colorectal Cancer
  • Stage IIIC Gastric Cancer
  • Stage IV Gastric Cancer
  • Stage IVA Colorectal Cancer
  • Stage IVA Liver Cancer
  • Stage IVA Pancreatic Cancer
  • Stage IVB Colorectal Cancer
  • Stage IVB Liver Cancer
  • Stage IVB Pancreatic Cancer
  • Stomach Neoplasms

Intervention

Other:
Computer-Assisted Intervention
Complete online surveys
Device:
Vivofit watch
Wear Vivofit watch
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean time patients are able to tolerate wearing the wristband device, both before and after surgery Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. Up to 1 month
Primary Mean time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure Descriptive statistics will be used to describe the distribution of time to complete each assessment. Up to 1 month
Primary Median time patients are able to tolerate wearing the wristband device, both before and after surgery Descriptive statistics will be used to describe the distribution of time (before and after surgery) a patient is able to wear the wristband device. Up to 1 month
Primary Median time to complete the web based questionnaires MDASI and EQ-5D, as well as the Self Geriatric Assessment Measure Descriptive statistics will be used to describe the distribution of time to complete each assessment. Up to 1 month
Primary Percentage of patients who are able to complete the web-based questionnaires MDASI and EQ-5D Descriptive statistics will be reported. Patients who complete at least 80% of all scheduled MDASI and EQ-5D questionnaires will be indicated as able to complete the web-based questionnaires. The true population proportion will be estimated with 95% confidence interval of half-width no more than 0.16. Up to 1 month
Primary Percentage of patients who are able to wear the wristband device for at least 1 week post-operatively Estimated with 95% confidence interval of half-width no more than 16%. Up to 1 week post-operatively
Secondary Ease of use of web-based surveys and wristband device, as measured by responses from Satisfaction Tool Up to 1 month
Secondary Feedback on items in the web-based surveys that are distressing or difficult to comprehend, as measured by responses from Satisfaction Tool Up to 1 month
Secondary Feedback on length of surveys and timing of administration, as measured by responses from Satisfaction Tool Up to 1 month
Secondary Mean number of missing items within each questionnaire Mean number of missing items within each questionnaire will be calculated to identify individual or subsets of questions that are difficult to answer. Up to 1 month
Secondary Percentage of patients who did not enroll in the study-composite outcome of multiple measure listed Percentage of patients who did not enroll in the study will be determined and the reasons why will be analyzed. This will be accomplished using: i) the number of patients asked to participate, ii) the number of patients who declined to participate, and iii) reasons for declining participation. Up to 1 month
Secondary Suggestions for items that were not covered but should be added, as measured by responses from Satisfaction Tool Up to 1 month
See also
  Status Clinical Trial Phase
Completed NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Phase 2
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00020345 - Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas Phase 2
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Completed NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Early Phase 1
Completed NCT01068327 - Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Phase 1
Completed NCT02307539 - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer N/A
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT00026104 - Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03899649 - A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
Completed NCT01821612 - Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Early Phase 1
Terminated NCT01739439 - Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Recruiting NCT00323583 - Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A